Vascular anomalies include various diseases, which are classified into two types according
to the International Society for the Study of Vascular Anomalies (ISSVA) classification …

Infantile hemangioma is a vascular tumor that occurs in 5–10% of infants of European
descent. A defining feature of infantile hemangioma is the dramatic growth and development …

Vascularization of tissues is a major challenge of tissue engineering (TE). We hypothesize
that blood-derived endothelial progenitor cells (EPCs) have the required proliferative and …

Background Corticosteroids are commonly used to treat infantile hemangioma, but the
mechanism of action of this therapy is unknown. We investigated the effect of corticosteroids …

Infantile hemangiomas are localized and rapidly growing regions of disorganized
angiogenesis. We show that expression of vascular endothelial growth factor receptor-1 …

Infantile hemangioma is a benign endothelial tumor composed of disorganized blood
vessels. It exhibits a unique life cycle of rapid postnatal growth followed by slow regression …

Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are
composed of R (+) and S (–) enantiomers: the R (+) enantiomer is largely devoid of beta …

The exact molecular mechanism of how endostatin inhibits angiogenesis and tumor growth
remains uncharacterized. Here, we report that endostatin specifically binds to the cell …

To ensure survival of engineered implantable tissues thicker than approximately 2–3 mm,
convection of nutrients and waste products to enhance the rate of transport will be required …

Migration of endothelial precursor cells (so-called “angioblasts” in embryos and “endothelial
progenitor cells” in adults) during vasculogenesis is a requirement for the formation of a …